CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-30 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +15,000 | $23.26 | $349K | 73,555 |
| 2026-04-30 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −15,000 | $63.26 | $949K | 58,555 |
| 2026-04-30 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −15,000 | 54,000 | ||
| 2026-04-29 | Blum Robert I President & CEO | Sale 10b5-1 | −7,500 | $59.62 | $447K | 407,830 |
| 2026-04-21 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +3,500 | $7.80 | $27K | 157,402 |
| 2026-04-21 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −3,500 | $65.69 | $230K | 153,902 |
| 2026-04-21 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −3,500 | 54,886 | ||
| 2026-04-15 | Wysenski Nancy Director | Grant or award | +95 | $65.37 | $6K | 31,066 |
| 2026-04-15 | WIERENGA WENDELL Director | Grant or award | +95 | $65.37 | $6K | 32,637 |
| 2026-04-15 | Kaye Edward M. MD Director | Grant or award | +191 | $65.37 | $12K | 10,365 |
| 2026-04-15 | HENDERSON JOHN T Director | Grant or award | +325 | $65.37 | $21K | 75,237 |
| 2026-04-15 | Harrington Robert Arthur Director | Grant or award | +191 | $65.37 | $12K | 18,930 |
| 2026-04-15 | Daly James M Director | Grant or award | +191 | $65.37 | $12K | 388 |
| 2026-04-15 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −7,449 | $66.02 | $492K | 58,555 |
| 2026-04-15 | Blum Robert I President & CEO | Sale 10b5-1 | −7,500 | $65.38 | $490K | 415,330 |
| 2026-04-07 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +3,500 | $7.80 | $27K | 157,402 |
| 2026-04-07 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −3,500 | $65.21 | $228K | 153,902 |
| 2026-04-07 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +1,000 | $10.60 | $11K | 154,902 |
| 2026-04-07 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −1,000 | $64.75 | $65K | 153,902 |
| 2026-04-07 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −3,500 | 58,386 |
Page 9 of 22 · 429 trades